The immunocheckpoints in modern oncology: The next 15 years

Expert Opinion on Biological Therapy

Volumn 15, Issue 7, 2015, Pages 917-921

  Massari, Francesco ^a   Santoni, Matteo ^b   Ciccarese, Chiara ^a   Santini, Daniele ^c  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Anti programmed death 1 and programmed death ligand 1; Immunocheckpoints; Immunoediting; Ipilimumab

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 2; PROGRAMMED DEATH 1 LIGAND 1; ANTINEOPLASTIC AGENT; IPILIMUMAB; MONOCLONAL ANTIBODY; NIVOLUMAB; PEMBROLIZUMAB;

ACTIVE IMMUNIZATION; ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RESEARCH; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL ACTIVITY; CELL DEATH; CELL PROLIFERATION; CELL SURFACE; CYTOTOXIC T LYMPHOCYTE; HLA TYPING; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOSURVEILLANCE; KIDNEY CARCINOMA; MELANOMA; MOLECULARLY TARGETED THERAPY; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; REGULATORY T LYMPHOCYTE; REVIEW; TREATMENT RESPONSE; TUMOR CELL; TUMOR ESCAPE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASMS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; CTLA-4 ANTIGEN; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84931043388     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2015.1035251     Document Type: Review

References (30)

1. Farber S, Diamond LK. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med 1948;238:787-93
2. Yadav M, Jhunjhunwala S, Phung QT, et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 2014;515:572-6
3. Cheever MA, Allison JP, Ferris AS, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009;15:5323-37
4. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3(11):991-8
5. Santoni M, Massari F, Amantini C, et al. Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother 2013;62:1757-68
6. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54
7. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65
8. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23
9. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372:320-30
10. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-33
11. Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol 2014. [Epub ahead of print]
12. Massari F, Santoni M, Ciccarese C, et al. PD-1 blockade therapy in renal cell carcinoma: Current studies and future promises. Cancer Treat Rev 2015;41(2):114-21
13. Zielinski C, Knapp S, Mascaux C, et al. Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer. Ann Oncol 2013;24:1170-9
14. Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014;515:558-62
15. Yadav M, Jhunjhunwala S, Phung QT, et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 2014;515:572-6
16. Gubin MM, Zhang X, Schuster H, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014;515:577-81
17. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015;372(4):311-19
18. Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy. Clin Cancer Res 2014;20:5064-74
19. Choueiri TK, Figueroa DJ, Fay AP, et al. Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial. Clin Cancer Res 2014;21(5):1071-7
20. Grosso J, Horak CE, Inzunza D, et al. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538). J Clin Oncol 2013;31(Suppl):3016
21. Fay AP, Callea M, Gray KP, et al. PD-L1 expression in non-clear cell renal cell carcinoma. J Clin Oncol 2014;32(Suppl 4):abstr 424
22. Madore J, Vilain R, Menzies AM, et al. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell Melanoma Res 2014. [Epub ahead of print]
23. Shim HJ, Hwang JE, Jung SI, et al. Clinical impact of programmed cell death ligand 1 (PD-L1), programmed cell death 1 (PD-1), and CD8 expression in pancreatic cancer. J Clin Oncol 2014;32(Suppl):abstract e15258
24. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515:563-7
25. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568-71
26. Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014;371:2189-99
27. Schumacher TN, Kesmir C, van Buuren MM. Biomarkers in cancer immunotherapy. Cancer Cell 2015;27:12-14
28. Antonia SJ, Larkin J, Ascierto PA. Immuno-oncology combinations: a review of clinical experience and future prospects. Clin Cancer Res 2014;20:6258-68
29. Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012;12:237-51
30. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345:1655-9